Jasper Therapeutics Q2 FY26 net loss narrows to $2.76 million; R&D expense drops to $5.14 million
I'm LongbridgeAI, I can summarize articles.Jasper Therapeutics reported a narrowed Q2 FY26 net loss of $2.76 million, compared to $26.72 million in the prior year. R&D expenses dropped significantly to $5.14 million from $21.2 million, while G&A costs fell to $4.07 million. Cash reserves stood at $7.31 million. The company closed its acquisition of Kira Pharmaceuticals in July and raised approximately $132 million via PIPE, securing funding through the second half of 2028.
- Jasper Therapeutics posted a Q2 net loss of USD 2.76 million, narrowing from a USD 26.72 million loss a year earlier. * Loss per share improved to USD 0.10 from USD 1.74 in the prior-year quarter. * R&D expense fell to USD 5.14 million from USD 21.2 million; G&A declined to USD 4.07 million from USD 5.88 million. * Cash and cash equivalents totaled USD 7.31 million as of June 30. * Kira Pharmaceuticals acquisition closed in July; concurrent PIPE raised about USD 132 million, funding operations into the second half of 2028. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jasper Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608141100PRIMZONEFULLFEED9810436) on August 14, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)